



## Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

February 21, 2019

BOULDER, Colo., Feb. 21, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the SVB Leerink Partners 8<sup>th</sup> Annual Global Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.

**Event:** SVB Leerink Partners 8<sup>th</sup> Annual Global Healthcare Conference  
**Presenter:** Ron Squarer, Chief Executive Officer, Array BioPharma  
**Date:** Thursday, February 28, 2019  
**Time:** 10:00 a.m. Eastern Time  
**Webcast:** <http://wsw.com/webcast/leerink32/array/>

A replay of the presentation will also be accessible under the "Investors/Investor Calendar" section of the website at [www.arraybiopharma.com](http://www.arraybiopharma.com).

### About Array BioPharma

Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets BRAFTOVI<sup>®</sup> (encorafenib) capsules in combination with MEKTOVI<sup>®</sup> (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a *BRAF*<sup>V600E</sup> or *BRAF*<sup>V600K</sup> mutation in the United States and with partners in other major worldwide markets. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Eli Lilly), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi<sup>®</sup> (larotrectinib, partnered with Bayer AG) is approved in the United States and Ganovo<sup>®</sup> (danoprevir, partnered with Roche) is approved in China. For more information on Array, please visit [www.arraybiopharma.com](http://www.arraybiopharma.com) or follow @arraybiopharma on Twitter and LinkedIn.

BRAFTOVI<sup>®</sup> and MEKTOVI<sup>®</sup> are registered trademarks of Array BioPharma Inc. in the United States and various other countries. Vitrakvi<sup>®</sup> is a registered trademark of Bayer AG. All trademarks are properties of their respective owners.

### CONTACT:

Andrea N. Flynn, Ph.D.  
Senior Director, Investor Relations & Corporate Communications  
(303) 381-6600  
[ir@arraybiopharma.com](mailto:ir@arraybiopharma.com)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-8th-annual-svb-leerink-partners-global-healthcare-conference-300799914.html>

SOURCE Array BioPharma Inc.